Dr. David Margulies
David Margulies currently serves as Chairman of Q-State Biosciences. As a physician executive and entrepreneur with interests in computational biology, genetics, and neuroscience, David has founded and led multiple technology-based health services companies. In the 1980s, he created the first clinical computing programs at both Columbia Presbyterian Medical Center and Boston Children’s Hospital, serving as Boston Children’s Hospital’s first Chief Information Officer. He then served as Executive Vice President, Chief Scientist, and Director of Cerner Corporation. David also co-founded and served in leadership roles at CareInsite (now WebMD), Correlagen Diagnostics (acquired by LabCorp), Generation Health (acquired by CVS/Caremark), and Claritas Genomics (now QnA Diagnostics). More recently, David returned to Boston Children’s Hospital as Vice President of Strategy and co-founded and served as Chief Executive Officer at Q-State Biosciences. David is a graduate of Amherst College and Harvard Medical School, and board certified in Internal Medicine. He holds an appointment as Assistant Professor at Harvard Medical School in the Department of Bioinformatics and at Boston Children’s Hospital in the Division of Genetics.
Mark Evenstad is the Founder and CEO of MOBE. He is driven by a simple mission – to help people achieve better health and greater happiness. Through MOBE, Mark lead his team to develop a sophisticated algorithm that detects specific people within a population who are poorly served by their current treatments. Then, the MOBE team works closely with each individual to improve their wellness and empower them to live their best life. Outside of MOBE, Mark has been focused on creating companies that deliver better health for the people they serve. His career most recently includes leading Upsher-Smith Laboratories as Director and CEO for more than 15 years, founding and serving as Board Chairman of Pairnomix, and currently serving as Board Chairman of ACOVA Integrated Health, Plymouth Guarantee, and Proximagen. He also serves as Director of Q-State Biosciences. Mark holds a B.A. and an M.B.A. from the University of St. Thomas in St. Paul, MN.
Jonathan Fleming is currently the Chief Business Officer at Q-State Biosciences, where he is responsible for establishing partnerships that will deliver revenue and further the company’s strategic objectives. Jonathan also serves as the Executive Chairman of QurAlis Inc. and Enclear Therapies, two ALS precision medicine companies that were spun out of Q-State Biosciences, and as a director of several other biotechnology companies, including SQZ Biotech and Continuus Pharmaceuticals. He has been a life science entrepreneur for more than 33 years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to his current roles, Jonathan was Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, which raised over $1 billion in early stage capital resulting in 21 IPOs and over 40 M&A transactions. He also co-founded several companies including Synaptic Pharmaceuticals (acquired by Lundbeck), Memory Pharmaceuticals (acquired by Roche), and Hypnion Pharmaceuticals (acquired by Lilly). Jonathan has been a senior lecturer at the MIT Sloan School of Management since 2002, where he co-teaches a course on business strategy for life science managers. He holds a Master’s degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs, and a Bachelor’s degree in Political Science from the University of California, Berkeley.
Dave Knudson is Senior Vice President and Chief Legal Counsel at United National Corporation, where he provides legal and advisory services to the company. Prior to this role, he served as Sr. Vice President – Strategic Advisor for Sanford Health, the largest rural not-for-profit healthcare system in the country. He also practiced law for 35 years at Davenport, Evans, Hurwitz and Smith in Sioux Falls, focusing on healthcare, banking and corporate transactions. Throughout his career as a lawyer and advisor, Dave has worked closely with Mr. Denny Sanford, founder and chairman of United National Corporation and benefactor of Sanford Health, to organize more than $1.5 billion in charitable gifts to various non-profits. Dave has a long-time interest in public service. He was Chief of Staff to South Dakota Governor Bill Janklow in 1995 and 1999, served four terms in the South Dakota State Senate, and served as the Senate Majority Leader from 2007 to 2010. He ran unsuccessfully in the 2010 Republican primary for Governor of South Dakota. He also served on the board of several organizations, including the Sioux Falls Development Foundation and the Sioux Falls Area Chamber of Commerce. A native of Yankton, South Dakota, Dave is a graduate of Harvard College and the New York University School of Law. He received an M.B.A. from the University of South Dakota School of Business.
Steven Hyman currently serves as the director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard and is the Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology. In addition to these roles, Steven is President of the American College of Neuropsychopharmacology, a Distinguished Life Fellow of the American Psychiatric Association, a fellow of the American Academy of Arts and Sciences, and a member of the National Academy of Medicine. Previously, Steven served as provost of Harvard University from 2001 to 2011 and as Director of the National Institute of Mental Health (NIMH) from 1996 to 2001. He holds a B.A. from Yale University, an M.A. from the University of Cambridge, and an M.D. from Harvard Medical School.
Dr. Jonathan Thomas
Jonathan Thomas (“JT”) is the Chair of the Governing Board of the California Institute for Regenerative Medicine (CIRM), a public agency dedicated to advancing stem cell research and developing cures for people in need. As head of the board, JT is responsible for all aspects of CIRM’s $3 billion funding program. Before joining CIRM he was a Co-Founding Partner at Saybrook Capital, an investment banking and private equity firm, where he led an early round of financing for Advanced Cell Technology (now Ocata Therapeutics). JT’s legal experience includes clerking for White House Counsel Lloyd Cutler in the last year of the Carter Administration and clerking for the Honorable George Mackinnon of the United States Circuit Court of Appeals for the District of Columbia Circuit. JT holds a Bachelor’s degree from Yale University where he graduated summa cum laude, a J.D. from Yale, and a Ph.D. from Oxford University, where he was a George C. Marshall Scholar.
Andrew Ross is a lifelong entrepreneur and private investor with a focus on early-stage investments in biotechnology, collaborative consumption, cause-focused enterprise.
Chad Martinson currently serves as CEO of ACOVA Integrated Health, a company dedicated to delivering better health outcomes for individuals living with chronic conditions. As CEO, Chad directs ACOVA’s long-term growth planning by building strong industry relationships and sourcing new business development opportunities that compliment and add value to the company. Chad currently also serves as Director of Q-State Biosciences, Pairnomix, Proximagen, MOBE and Plymouth Guarantee. Prior to joining ACOVA, Chad held a number of leadership roles in the fields of corporate finance, business unit finance, sales and marketing, and operations. Most recently, Chad served as CFO and Executive Vice President of Operations at Upsher-Smith Laboratories and Director of Pairnomix. He also previously served as VP of Finance and Business Development at Medtronic in the company’s neuro division, and spent eight years at KPMG in the audit practice. He holds a B.A. from Luther College in Decorah, Iowa, and an M.B.A. from Harvard Business School in Boston, Massachusetts.
As Chief Executive Officer of Q-State Biosciences, Matthew Fox is responsible for overseeing the company’s operations, developing the growth strategy, and delivering revenue. Most recently, Matthew co-founded Pairnomix and led the personalized research company as Chief Executive Officer. While at Pairnomix, he helped build the market for personalized research services and grew the brand until it combined with Q-State. Prior to joining Pairnomix, Matthew served as Senior Vice President of Corporate Strategy at Upsher-Smith Laboratories, where he led business intelligence efforts, developed and maintained trade and advocacy partnerships, and sourced new opportunities to expand and grow the business. Prior to that role, Matthew served as a Portfolio Manager at Bank am Bellevue in Zurich, Switzerland, investing in global biotechnology and pharmaceutical companies. He holds a B.A. in Neuroscience and Behavior from Wesleyan University in Middletown, Connecticut.